Milan

• Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz … Recruiting
  2022-503148-41-00 4 2023-12-01 Alzheimer's disease
• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 5 2023-11-16 Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis o
• A Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with Specific KIT Exon Mutations Who Were … Recruiting
  2022-503058-37-00 5 2023-11-10 Advanced Gastrointestinal Stromal Tumor
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) … Recruiting
  2022-501100-94-00 5 2023-11-08 Episodic Migraine
• A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicit … Recruiting
  2022-501882-29-00 5 2023-11-03 Generalized Myasthenia Gravis (gMG)
• Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation: t … Recruiting
  2023-508123-12-00 10 2023-11-03 Post-Acute COVID Syndrome (PACS)
• A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c … Recruiting
  2023-504265-23-00 4 2023-10-23 Crohn's disease
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 4 2023-10-17 Large cell neuroendocrine carcinoma
• A clinical study of ABSK021 in Patients with Tenosynovial Giant Cell Tumor to determine whether the study drug is safe and how well the ant … Recruiting
  2023-503245-58-00 5 2023-10-04 Tenosynovial Giant Cell Tumor
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 5 2023-09-28 marginal zone lymphoma
• A study to learn how safe the study treatment actinium-225-macropa-pelgifatamab (BAY3546828) is, how it affects the body, how it moves into, … Recruiting
  2022-502623-22-00 1 2023-09-18 Metastatic castration-resistant prostate cancer
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 4 2023-09-05 Bronchiectasis
• Clinical study to investigate the Efficacy and Safety of Encaleret Compared to Standard of Care treatment in patients with Autosomal Dominan … Recruiting
  2022-501398-38-00 5 2023-09-02 Autosomal Dominant Hypocalcemia Type 1 (ADH1)
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Phase 1/2 Open Label solid tumour Safety and Tolerability study in Pediatric and Young Adult subjects. Recruiting
  2023-506464-14-00 9 2023-06-29 Advanced solid tumors
• Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimeta … Recruiting
  2023-503322-39-00 3 2023-06-16 Newly diagnosed patients with metastatic (other than lung/pleura metas
• Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting
  2022-500266-10-00 5 2023-06-13 Recessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epider
• A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease Recruiting
  2022-500718-24-00 5 2023-06-09 IgG4-Related Disease
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting
  2023-510275-64-00 9 2023-05-31 Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or ot
• A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting
  2024-510635-21-00 5 2023-05-09 warm autoimmune haemolytic anaemia (wAIHA)
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS … Recruiting
  2022-500479-29-00 10 2023-03-28 International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte

Showing 409–432 of 2,361 trials